Anapen® Junior 150 and Anapen® 300 will no longer be sold or distributed in Australia, “due to lack of demand for a second brand of adrenaline autoinjector for the 150mcg and 300mcg strengths,” its manufacturer announced this week.
“This decision is voluntary and not related to any quality, safety or efficacy issues regarding the products,” Arrotex Pharmaceuticals general manager for marketing said in a letter to health professionals, adding that the company will focus instead on the 500mcg strength.
The Anapen® Junior 150 will be available until the end of September 2024, while Anapen® 300 will only be available until the end of July 2024. Both products are ‘a’ flagged to their EpiPen equivalent, so after these dates pharmacists can substitute with EpiPen Junior and EpiPen2 (with appropriate training).
Anapen® 500 and Anapen® Trainer devices will remain available. Arrotex has reassured the public that it will continue to supply Anapen® 500, which is the only 500mcg adrenaline autoinjector available on the PBS.
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
You have completed the Educational Activities (EA) component of this activity.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.
